Latest Research Collaboration News

Legacy Minerals delivers a robust scoping study for Mt Carrington with A$514 million pre-tax NPV, confirms a new gold-silver discovery at Mascotte, and advances multiple drilling programs across NSW projects.

Unith Ltd boosted its AI digital human platform with ISO/IEC 27001:2022 certification, launched new SDKs, and secured $2.75 million in fresh capital to fuel growth and commercial expansion.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

Mount Ridley Mines secures $50,000 co-funding from CSIRO to kick-start research on scandium alloys for additive manufacturing, leveraging one of the world’s largest scandium resources at Grass Patch.

Strategic Elements has achieved a significant milestone with the granting of a patent in Japan for its Energy Ink™ moisture energy platform, reinforcing its foothold in a critical electronics market and advancing its battery-free device ambitions.

NoviqTech Limited has clarified that its planned divestment of Non-Coralia assets was not foreseen during its Coralia acquisition and reflects a strategic pivot to biochar carbon removal, with leadership changes aligned to this refocus.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Echo IQ has partnered with Mayo Clinic to assess its AI platform's ability to predict heart failure risk in patients undergoing cancer therapy, targeting the growing cardio-oncology sector.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.